Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference

Diana R. Kerwin, MD
Assistant Professor of Medicine-Geriatrics
Cognitive Neurology and Alzheimer’s Disease Center
Northwestern University Feinberg School of Medicine
March 24, 2012

Objectives

- Define and clarify nomenclature
  - Frontotemporal disorders
    - Behavioral variant frontotemporal degeneration (bvFTD)
    - Primary progressive aphasia (PPA)
      - Agrammatic/Non-fluent
      - Logopenic
      - Semantic
    - FTD with motor abnormalities
      - Corticobasal degeneration
      - Progressive supranuclear palsy
      - FTD with motor neuron disease (FTD-MND)
        » Amyotrophic lateral sclerosis (FTD-ALS)

Objectives continued:

- Discuss diagnostic evaluation and ancillary testing
- Neuroimaging
- Discussion of role of genetics and genetic testing in certain cases
- Treatments
- Current research and future plans

Dementia

- A general term for:
  1) The loss of memory or other thinking skills
  2) Significantly interferes with daily life (work, school, family)

Clinical syndromes caused by Neurodegenerative Disease

Clinical Dementia of the Alzheimer’s Type

Primary Progressive Aphasia (PPA)

Behavioral Variant Frontotemporal Degeneration (bvFTD)

Diversity

Clinical Syndromes caused by Neurodegenerative Disease

bvFTD:

Diagnostic criteria

- Established clinical consensus criteria (Rascovsky et al., Brain 2011; 134:2456-77)
- Core features
  - Insidious onset and slow progression
  - Three of the following must be present
    - Behavioral disinhibition
    - Apathy or inertia
    - Loss of sympathy or empathy
    - Perservative or ritualistic behavior
    - Hyperorality or dietary changes
    - Problems with executive function but spared memory and visuospatial functions
How is the diagnosis made in bvFTD and PPA?

- Neurologic examination
  - Caregiver input is very important
  - Differential diagnosis of dementias in younger patients is often more broad
  - Additional testing maybe needed:
    - Lumbar puncture (spinal fluid analysis for Tau and amyloid)
    - Electroencephalogram (EEG)
    - Other blood tests
    - Genetic testing in some cases

What is neuropsychological testing?

- A battery of paper and pencil type tests designed to diagnose brain dysfunction by examining performance on tasks that model actual cognitive actions.
- Normed for the persons intelligence, age, education
- Can be 2-4 hours of testing
- Reliable
- Medicare covered

Elements of Executive Function

- Planning
- Abstract thinking
- Sequencing
- Monitoring
- Stopping complex behavior

bvFTD Diagnostic evaluations

- Neuropsychology:
  - Impaired frontal lobe tests in absence of severe amnesia, aphasia, or visuospatial deficits
  - Executive dysfunction often prominent
- Imaging:
  - Atrophy or decreased uptake in the frontal or anterior temporal lobes (bilateral or unilateral) by MRI, CT, PET, SPECT (The Lund and Manchester Groups, J Neurol Neurosurg Psychiatry 1994;57:416-418; Neary et. al, Neurology 1998;51:1246-1254)

PPA Diagnostic evaluations

- Neuropsychology:
  - Impairment is prominent in a single domain (language) with relative sparing of other domains early on (e.g., memory, personality, and perception)
- Imaging:
  - Focal atrophy in the left Temporal lobe
### Neuroimaging

- **Anatomic MRI**
  - This is the most commonly used
- **FDG-PET**
  - Currently Medicare approved, other insurers require pre-certification for coverage
- **Amyloid-PET**
  - Used in Alzheimer’s diagnosis
- **FDDNP**

### bvFTD Anatomic MRI

![bvFTD Anatomic MRI](image)

### Neuroimaging and Dementia

American Academy of Neurology Practice Parameter Guidelines recommend structural imaging in initial evaluation of patients with dementia.

1. Positron emission tomography (PET) of fluorodeoxyglucose (FDG) may help differentiate Alzheimer’s disease (AD) from frontotemporal dementia (FTD).

Other PET imaging technologies are currently under development.


### MRI: AD                       FTD

- **AD**
- **FTD**

 Chan, Neurology 2001

### Neuropathology in PPA & bvFTD

- The term “frontotemporal lobar degeneration” (FTLD) is used to describe the specific pathological diseases that result in FTD syndromes. These too are united by their impact on frontal and temporal brain structures.
  - Subtyping is based on the specific proteins found within neuronal inclusions. Most FTLD subtypes are either:
    - FTLD-tau, which includes Pick’s disease, CBD and PSP, all of which show tau-containing inclusions or
    - FTLD-TDP, which includes several subtypes in which TDP-43 containing inclusions are seen
  - In addition to FTLD pathology PPA can be caused by AD:

- Alzheimer Pathology
- FTLD-T
- TDP-43

### Genetics

- Approximately 50% of FTD cases are inherited
- 15% cases are inherited due to inheriting the gene and developing FTD
- 15% cases are sporadic
- Familiar cases have a general autosomal dominant risk
- 20-40% of FTD cases are familial
- May be inherited
- Pedigree numbers are increased, though undetermined risk, probably due to undiagnosed neurodegenerative genes

---

Copyright 2012. Do not distribute or replicate without permission
### Role of Genetics

- **1999 study** showed of 42 FTD cases, 19 had at least 1 other family member affected
  - 1/3 had a positive family history in this study, however other studies lower
  - Showed an autosomal dominant inheritance
- **Linked to chromosome 17** (tau gene) and chromosome 3
- Progranulin (PRGN) gene mutation linked with ubiquitin inclusions
  - Seen in both PPA and FTD
- Association with ALS (FTD-MND)
  - Chromosome 9

### FTD Genetics Recap

- **Chromosome 17**
  - MAPT gene mutation ⇒ tau positive inclusions
    - Not shown specifically in PPA
- **PRGN gene mutation** ⇒ ubiquitin inclusions
  - Has been shown in both PPA and FTD families

### Frontotemporal Disorders

- **Implications for bvFTD/PPA different from other dementias/AD:**
  - Younger age at onset
  - Often person is mid-career and disability/ legal issues
  - Greater caregiver burden and increased dependency and health care costs due to the nature of the conditions

### bvFTD/PPA Treatments

- **Cognitive enhancers**
  - When Alzheimer’s treatments may be used
    - The Memantine clinical trial and others
- **Behavioral treatments**
  - Antidepressants
  - Antipsychotics
  - Mood stabilizers
- **Supportive therapies**
  - Speech, Occupational, Physical, Cognitive

### Why investigate symptomatic treatments for FTD?

- No disease-modifying treatments for FTD
- Symptomatic treatments are in common use
- Improve quality of life for patients and families
- Even if we develop disease-modifying treatments, we will still need symptomatic treatments
- Symptomatic and disease-modifying treatments are not mutually exclusive and the distinction may not always be clear

### Comparison of prescribed treatments

<table>
<thead>
<tr>
<th></th>
<th>Bv-FTD</th>
<th>AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitor</td>
<td>41%</td>
<td>55%</td>
</tr>
<tr>
<td>Memantine</td>
<td>30%</td>
<td>28%</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>43%</td>
<td>30%</td>
</tr>
<tr>
<td>Anxiolytic</td>
<td>7%</td>
<td>11%</td>
</tr>
<tr>
<td>Antipsychotic</td>
<td>5%</td>
<td>10%</td>
</tr>
</tbody>
</table>
“Borrowed” treatments for FTD

<table>
<thead>
<tr>
<th>Repetitive behaviors</th>
<th>Treatment</th>
<th>Borrowed from</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apathy</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Empathy</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Socially inappropriate behaviors / agitation</td>
<td>Antidepressants / atypical antipsychotic</td>
<td>AD</td>
</tr>
<tr>
<td>Expressive aphasia</td>
<td>Speech therapy</td>
<td>Stroke</td>
</tr>
<tr>
<td>Hyperphagia</td>
<td>SSRI</td>
<td>Impulse-control psychiatric disorders</td>
</tr>
<tr>
<td>Executive dysfunction</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>Memantine</td>
<td>AD</td>
</tr>
</tbody>
</table>

Medications for FTD

- Cholinesterase inhibitors
  - Results and effects contradictory, not currently recommended
- Memantine
  - Well tolerated in three open label trials and a randomized, double-blinded placebo controlled trial
  - May improve behavioral symptoms
  - Awaiting current clinical trial results

Antidepressants

Forest Plot of Mean NPI Difference

- Citalopram
  - Improved irritability, depressed mood, disinhibition
- Fluvoxamine
  - 12 wk study showed significant improvement in behavioral symptoms
- Sertraline
  - Reduced verbal and motor stereotypic behaviors
- Others: paroxetine, trazodone, Lexapro

Atypical antipsychotics

- Generally, a second-line agent after antidepressants for behavioral symptoms
- In dementia, small effect size on behavioral symptoms (0.1 to 0.2)\(^1\)
- Increased OR of death of 1.54 (95% CI, 1.06-2.23; NNH = 87)\(^1\)
- Should be used very carefully due to potential severe adverse events
  - Cardiovascular, worsening motor, stroke

1. Maher et al., JAMA, 2011

Atypical antipsychotics, cont

- Risperidone
  - Range: 0.5-2.5 mg
  - Can have more EPS than other atypicals at higher doses
- Quetiapine
  - Range: 50-200 mg
  - Sedating, possibly less efficacious
- Olanzapine
  - Range: 2-10 mg
  - Limited use in FTD because of appetite increase
- Aripiprazole
  - Range: 2-15 mg
Pro-dopaminergic medications

- Few trials, but early evidence of improvement of behavioral symptoms\(^1,2\)
- Dopamine-agonist bromocriptine in PPA
  - A clinical trial of bromocriptine for treatment of primary progressive aphasia: \(\text{Ann Neurol.} 2004\text{ Nov};56(5):750\).

1. Rahman et al., \text{Neuropsychopharmacology}, 2006

Tailored medication treatment for FTD syndromes

<table>
<thead>
<tr>
<th>Behavior</th>
<th>Current</th>
<th>Future</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repetitive behaviors</td>
<td>SSRI</td>
<td>SSRI</td>
</tr>
<tr>
<td>Apathy</td>
<td>None</td>
<td>? Pro-dopaminergic meds</td>
</tr>
<tr>
<td>Empathy</td>
<td>None</td>
<td>Oxytocin</td>
</tr>
<tr>
<td>Socially inappropriate behaviors</td>
<td>SSRI / atypical antipsychotic</td>
<td>SSRI / atypical antipsychotic</td>
</tr>
<tr>
<td>Expressive aphasia</td>
<td>Speech therapy</td>
<td>Speech therapy</td>
</tr>
<tr>
<td>Hyperphagia</td>
<td>SSRI</td>
<td>SSRI</td>
</tr>
<tr>
<td>Executive dysfunction</td>
<td>None</td>
<td>? pro-dopaminergic meds</td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>None</td>
<td>Memantine</td>
</tr>
</tbody>
</table>

Future directions

- Tau treatments
  - Davenutide
  - GSK3, lithium, valproate
  - Methyl blue
  - Epothilone D
- Coenzyme Q 10
- Non-pharmacologic therapies
  - Direct brain treatments (e.g. TMS)
  - Behavioral interventions

Conclusion

- Final remarks
- Question and answer session
- Thank you!

Other Resources & Support

- Cognitive Neurology and Alzheimer’s Disease Center
  - [www.brain.northwestern.edu](http://www.brain.northwestern.edu)
  - A list of programs, educational support and Resources
- The Association for Frontotemporal Degeneration (AFTD)
  - [www.ftd-picks.org](http://www.ftd-picks.org)
  - Serves as a hub for distributing news relevant to FTD and PPA
- National Aphasia Association
  - [www.aphasia.org](http://www.aphasia.org)
  - Promotes education, research and support relevant to PPA
- FTDP-PPA Caregiver & Professional Education Conference
- International PPA Registry:

- Provides clinicians and researchers with a platform for exchanging knowledge about the latest developments in FTD
- The multidisciplinary program will address clinical diagnosis, management and care, epidemiology and neuropsychology, as well as other disciplines.
- The FTD conference will also feature a one day caregiver program for family members/FTD caregivers designed to provide education and offer support to those in close contact with this currently untreatable degenerative brain disease.

[http://www2.kenes.com/ftd2012/Pages/Home.aspx](http://www2.kenes.com/ftd2012/Pages/Home.aspx)

Manchester, UK
September 5th–7th, 2012

Provides clinicians and researchers with a platform for exchanging knowledge about the latest developments in FTD
The multidisciplinary program will address clinical diagnosis, management and care, epidemiology and neuropsychology, as well as other disciplines.
The FTD conference will also feature a one day caregiver program for family members/FTD caregivers designed to provide education and offer support to those in close contact with this currently untreatable degenerative brain disease.